Subscribe To
KONEF / Wellbeing Digital Sciences delivers first IV ketamine treatment under new in-patient program
KONEF News
By Proactive Investors
June 19, 2023
Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) told investors it has struck a deal to sell its wholly-owned KGK Science subsidiary to Card more_horizontal
By Proactive Investors
April 18, 2023
Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) reported that its subsidiary KGK Science on behalf of its client Nova Mentis has commenced pati more_horizontal
By Proactive Investors
March 8, 2023
Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned KGK Sciences Inc (KGK) subsidiary has applied for a Controlled more_horizontal
By Proactive Investors
February 15, 2023
Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) told investors its subsidiary KGK Science Inc (KGK) has completed preclinical safety studies fo more_horizontal
By Proactive Investors
February 14, 2023
Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) said its wholly-owned subsidiary KGK Sciences Inc. has received an exemption under Section 56 more_horizontal
By Proactive Investors
December 23, 2022
Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection le more_horizontal
By Proactive Investors
December 8, 2022
Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly owned subsidiary KGK Science Inc has been awarded an institution-wide canna more_horizontal
By Proactive Investors
December 6, 2022
Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that a clinical study conducted by wholly-owned subsidiary KGK Science Inc has shown more_horizontal